FREMONT, Calif., May 9, 2016 — Quark Pharmaceuticals, Inc. (“Quark”) today announced a keynote address on the company’s history of oligonucleotide development will be presented at the 18TH Annual TIDES Oligonucleotide and Peptide Therapeutics Conference at 11 a.m. PDT on May 10 at the Long Beach Convention Center in Long Beach, CA. Daniel Zurr, Ph.D., Chairman and Chief Executive Officer of Quark will present the talk entitled Quark’s Long History of Oligonucleotide Development.
“We have made significant progress with our siRNA platform and product candidates and we now have two product candidates in Phase III clinical trials,” said Daniel Zurr, Ph.D., Chairman and Chief Executive Officer of Quark Pharmaceuticals. “We look forward to presenting our significant evolution from a research-stage to a late clinical-stage siRNA company to our industry peers at this important conference.”
Quark will also be presenting at one workshop and one presentation session. These presentations provide an overview of Quark’s achievements in becoming a leading late clinical-stage company in RNAi therapeutics, the first company receiving regulatory approvals to initiate clinical trials with siRNA drugs in China and India and in generation of rich pre-clinical pipeline focused on extrahepatic indications.
Below is the schedule of the three presentations of Quark at the 18TH Annual TIDES Oligonucleotide and Peptide Therapeutics Conference:
Monday, May 9, 9:30 to 9:45 a.m. PDT: Title: Recent Regulatory Experience of an siRNA IND in India and China
Workshop #1: Current Topics on the Manufacturing and Quality Control of Oligonucleotides; Strategies for an Integrated Approach to Global Development
Presenter: Vidhya Gopalakrishnan, Ph.D, Senior Vice President, Quark Pharmaceuticals
Tuesday, May 10, 11:00 to 11:40 a.m. PDT. Title: Quark’s long History of Oligonucleotide Development.
Presenter: Daniel Zurr, Ph.D., Chairman and Chief Executive Officer, Quark Pharmaceuticals
Thursday, May 12, 10:45 to 11:15 a.m. PDT: Title: siRNA Therapeutics for Extrahepatic Indications
Session: Preclinical and Clinical Development Strategies
Presenter: Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, Quark Pharmaceuticals
IBC’s 18th Annual TIDES 2016 conference and exhibition, on May 9 to 12, is an industry forum for CMC, clinical and discovery scientists to share strategies to accelerate oligonucleotide and peptide product development. The conference provides complete coverage of the oligonucleotide and peptide market from discovery to manufacturing. Attendees learn from multiple case studies designed to facilitate scientific exchange and networking to improve oligo and peptide drug development and manufacturing operations. More information on the conference can be found at http://www.ibclifesciences.com/TIDES/overview.xml.
About Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. is a late clinical-stage pharmaceutical company, discovering and developing novel RNAi-based therapeutics for unmet medical needs. Two products, QPI -1002 and QP -1007 are in global phase III pivotal clinical studies for Delayed Graft Function (DGF) and Non Arteritic Ischemic Optic Neuropathy (NAION) for which each was granted Orphan designation, respectively. The Company is also conducting several Phase II clinical trials. Quark’s broad pipeline of clinical and preclinical product candidates is generated by the company’s internally developed technology, which includes Quark’s RNAi platform technology and its delivery to a host of organs. Quark is headquartered in Fremont, California and operates research facilities in Ness-Ziona, Israel. For additional information please visit: www.quarkpharma.com.
(858) 717-2310 Mobile
(917) 217-1838 Mobile